NIMBL
"Nuclease Immune Mediated Brain and Lupus-like conditions (NIMBL): natural history, pathophysiology, diagnostic and therapeutic modalities with application to other disorders of autoimmunity"
| Coordinatore | THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://www.nimbl.eu/ni/Home |
| Totale costo | 6˙978˙247 € |
| EC contributo | 5˙396˙993 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-06-01 - 2013-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | coordinator | 1˙379˙436.00 |
| 2 |
UNIVERSITY OF LEEDS
Organization address
address: WOODHOUSE LANE contact info |
UK (LEEDS) | participant | 748˙642.00 |
| 3 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 672˙947.00 |
| 4 |
UNIVERSITY OF WASHINGTON
Organization address
address: BROOKLYN AVENUE NE 4333 contact info |
US (SEATTLE WA) | participant | 667˙893.00 |
| 5 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 620˙162.00 |
| 6 |
FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
Organization address
address: CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA contact info |
ES (BARCELONA) | participant | 518˙651.40 |
| 7 |
Children's Research Institute (CRI)
Organization address
address: Michigan Avenue 111 contact info |
US ("Washington, DC") | participant | 357˙444.00 |
| 8 |
FONDAZIONE ISTITUTO NEUROLOGICO CASIMIRO MONDINO
Organization address
address: Via Mondino 2 contact info |
IT (PAVIA) | participant | 222˙489.00 |
| 9 |
UNIVERSITAT DE BARCELONA
Organization address
address: GRAN VIA DE LES CORTS CATALANES 585 contact info |
ES (BARCELONA) | participant | 209˙328.60 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Nuclease Immune Mediated Brain and Lupus-like (NIMBL) conditions, comprising Aicardi-Goutieres Syndrome, Retinal Vasculopathy with Cerebral Leukodystrophy and some cases of Systemic Lupus Erythematosus, are devastating genetic disorders resulting in greatly reduced quality of life, high mortality especially in children, and significant risks of recurrence within affected families. NIMBL conditions are rare, but under diagnosed. No effective treatments or cures exist at present. To enable optimum patient care in Europe and worldwide, a better understanding of the natural course of these disorders and their underlying pathological basis is essential. In the NIMBL project, European and U.S. clinical and basic scientists at the forefront of NIMBL-related research have united to develop a translational approach to these problems. A registry of patients will reveal the natural history of the NIMBL diseases, and the efficacy of current treatments. Investigation of patients together with the use of existing and novel cellular and animal models will precisely define their pathogenesis and identify potential drug targets. These same platforms will then be used to test existing and new drug treatments, thus providing unique opportunities to European companies. The NIMBL project will build on very recent discoveries of the cell-intrinsic initiation of autoimmunity that we have described, and which have major implications for our understanding of the discrimination of self from non-self. This new biological paradigm involves cytosolic sensors that detect accumulated, endogenous nucleic acids, and induce the body to mount an immune response against its own cells. Thus, the investigation of NIMBL diseases will not only improve the health and well-being of NIMBL patients and their families, it will also lead to better treatments of much more common autoimmune disorders including lupus.'